Download by
Scanning QR Code
No Stock Yet
No Data
Dongxing Securities: medical and Beauty Policy sends positive signals to promote Industrial Compliance Development
Haohai Biotechnology (06826.HK) lost 84600 shares by Kabouter Management LLC
Gelonghui, August 2-according to the latest disclosure of rights and interests of the Stock Exchange, on July 27th, 2022, Haohai Biotechnology (06826.HK) was reduced by Kabouter Management LLC at an average price of HK $35.66 per share, involving an investment of about HK $3.0168 million. After the reduction, the latest number of shares held by Kabouter Management LLC is 2.89045 million shares, which decreased from 8.19 per cent to 7.96 per cent.
Hao Hai Sheng Science (688366.SH) 2021 annual equity distribution of 10 yuan 7 yuan, equity registration date is August 8
688366.SH announced the implementation of the annual equity distribution in 2021, proposing to pay a cash dividend of 7 yuan (including tax) for every 10 shares. The date of equity registration is August 8, 2022, the date of excluding rights (interest) is August 9, 2022, and the date of cash dividend is August 9, 2022.
Hao Haisheng (688366.SH) pays out 7 yuan per 10 shares in 2021.
Zhitong Financial App News, 688366.SH issued an announcement that the annual profit distribution of the company in 2021 shall be based on the total share capital of the company before the implementation of the plan, with a cash dividend of 0.70 yuan per share (including tax), equity registration date 2022-8-8, excluding rights (interest) date 2022-8-9.
Haohaishengke: the subsidiary company plans to increase its capital and shares to implement the employee stock ownership plan
Hao Hai Sheng Science (688366.SH): Likangrui plans to increase capital and shares to implement employee stock ownership plan
688366.SH announced that Shanghai Likangrui Biological Engineering Co., Ltd. ("Likangrui"), a wholly owned subsidiary of the company, plans to increase its registered capital by 75 million yuan at the price of 2 yuan per share. Shanghai Shunanyuan Biotechnology Partnership (Limited Partnership) ("Shun Anyuan") (still under establishment) and Shanghai Kangdingchen Biotech Partnership (Limited Partnership) ("Kang Dingchen") as two employee shareholding platforms, it is proposed to subscribe for Likangrui registered capital of RMB 35 million yuan and RMB 4 respectively at RMB 70 million and RMB 80 million respectively.
Haohai Biotechnology (06826.HK) expects to make a net profit of about 65 million-78 million yuan in the first half of the year.
Gran Haohai Biotechnology (06826.HK) announced on July 29th that for the six months ended June 30, 2022, the Group is expected to realize unaudited net profit of about RMB 65 million to RMB 78 million, a decrease of about RMB 166 million to RMB 153 million compared with the same period in 2021, a decrease of about 71.86% to 66.24%. The expected net profit of unaudited shareholders of listed companies after deducting non-recurring profits and losses is about 50 million yuan to 60 million yuan, which is about less than that of the same period in 2021.
Haohai Biotechnology: profit forecast
The half-year net profit of 688366.SH is expected to decrease by 66.24% and 71.86%.
Gronghui Haisheng Science (688366.SH) announced on July 29 that the net profit attributed to the owner of the parent company in 2022 is expected to be 65 million yuan to 78 million yuan, a decrease of 166.0228 million yuan to 153.0228 million yuan compared with the same period last year, or 71.86% to 66.24% compared with the same period last year. It is estimated that the net profit attributable to the owner of the parent company after deducting non-recurring profits and losses for the first half of 2022 is RMB 50 million to RMB 60 million, which will be reduced by RMB 170.9875 million to RMB 160 compared with the same period last year.
Hao Haisheng Science (688366.SH) issued a pre-reduction, with a half-year net profit of 65 million yuan to 78 million yuan, a decrease of 71.86% to 66.24% over the same period last year.
Zitong Financial App News, 688366.SH issued a half-year performance forecast for 2022. According to preliminary estimates by the financial department, the net profit attributed to the owner of the parent company in the first half of 2022 is expected to be 65 million yuan to 78 million yuan, a decrease of 71.86% to 66.24% compared with the same period last year. The net profit attributable to the owner of the parent company after deducting non-recurring profits and losses is expected to be 50 million to 60 million yuan in the half of 2022, a decrease of 77.37% to 72.85% compared with the same period last year. The announcement said
Loading...
No Stock Yet